PT792643E - Derivados de benzimidazol sua preparacao e uso terapeutico - Google Patents

Derivados de benzimidazol sua preparacao e uso terapeutico

Info

Publication number: PT792643E
Authority: PT; Portugal
Prior art keywords: preparation; therapeutic use; benzimidazole derivatives; ischemia; mammal
Prior art date: 1996-02-29

Application number

PT97301172T

Other languages

English (en)

Inventor

Thomas A Beyer

Delvin R Knight Jr

Banavara L Mylari

Peter J Oates

Wayne R Tracey

Eric A Pettipher

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-02-29

Filing date

1997-02-21

Publication date

2002-08-30

1997-02-21 Application filed by Pfizer filed Critical Pfizer

2002-08-30 Publication of PT792643E publication Critical patent/PT792643E/pt

Links

229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
150000001556 benzimidazoles Chemical class 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1
229940118148 Aldose reductase inhibitor Drugs 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
239000003288 aldose reductase inhibitor Substances 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 abstract 1
210000005003 heart tissue Anatomy 0.000 abstract 1
208000028867 ischemia Diseases 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000000451 tissue damage Effects 0.000 abstract 1
231100000827 tissue damage Toxicity 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01021—Aldehyde reductase (1.1.1.21), i.e. aldose-reductase

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Plant Substances (AREA)

PT97301172T 1996-02-29 1997-02-21 Derivados de benzimidazol sua preparacao e uso terapeutico PT792643E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US1270796P	1996-02-29	1996-02-29

Publications (1)

Publication Number	Publication Date
PT792643E true PT792643E (pt)	2002-08-30

Family

ID=21756300

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT97301172T PT792643E (pt)	1996-02-29	1997-02-21	Derivados de benzimidazol sua preparacao e uso terapeutico

Country Status (14)

Country	Link
US (1)	US6127367A (pt)
EP (1)	EP0792643B1 (pt)
JP (1)	JPH09316003A (pt)
KR (1)	KR970061252A (pt)
CN (1)	CN1081460C (pt)
AT (1)	ATE216239T1 (pt)
AU (1)	AU724327B2 (pt)
CA (1)	CA2198564C (pt)
DE (1)	DE69711972T2 (pt)
DK (1)	DK0792643T3 (pt)
ES (1)	ES2172748T3 (pt)
IL (1)	IL120264A0 (pt)
PT (1)	PT792643E (pt)
ZA (1)	ZA971717B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0982306A3 (en) *	1998-08-21	2000-07-05	Pfizer Products Inc.	Polymorph of zopolrestat monohydrate
US7151102B2 (en)	2000-10-30	2006-12-19	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
WO2002098421A1 (en) *	2001-06-05	2002-12-12	University Of Maryland, Baltimore	Novel treatment for neurological and psychiatric disorders
DE60335359D1 (de)	2002-04-30	2011-01-27	Kudos Pharm Ltd	Phthalazinonderivate
GB0305681D0 (en)	2003-03-12	2003-04-16	Kudos Pharm Ltd	Phthalazinone derivatives
US7449464B2 (en)	2003-03-12	2008-11-11	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
GB0419072D0 (en)	2004-08-26	2004-09-29	Kudos Pharm Ltd	Phthalazinone derivatives
US20110092566A1 (en) *	2004-11-19	2011-04-21	Srivastava Satish K	Treatment of cancer with aldose reductase inhibitors
GB0521373D0 (en)	2005-10-20	2005-11-30	Kudos Pharm Ltd	Pthalazinone derivatives
WO2007069727A1 (ja) *	2005-12-16	2007-06-21	Sanwa Kagaku Kenkyusho Co., Ltd.	急性腎不全の予防または治療剤
EP1987829A4 (en) *	2006-02-20	2009-07-29	Sanwa Kagaku Kenkyusho Co	PROPHYLACTIC OR THERAPEUTIC AGENT FOR LESIONS DUE TO BRAIN ISCHEMIA OR LESIONS DUE TO BRAIN ISCHEMIA WITH REPERFUSION IN BRAIN VASCULAR ACCIDENTS
UY30639A1 (es)	2006-10-17	2008-05-31	Kudos Pharm Ltd	Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
EP2110141B1 (en) *	2007-01-31	2013-04-03	Sanwa Kagaku Kenkyusho Co., Ltd	Protective agent for retinal nerve or optic nerve
CA2685202C (en)	2007-03-23	2017-11-28	The Board Of Regents Of The University Of Texas System	Methods for treating allergic asthma
WO2009034326A1 (en)	2007-09-14	2009-03-19	Astrazeneca Ab	Phthalazinone derivatives
MX2010004028A (es)	2007-10-17	2010-04-30	Kudos Pharm Ltd	4-[3-(4-ciclopropancarbonil-piperacin-1-carbonil)-4-fluoro-bencil ]-2h-ftalacin-1-ona.
US20110236394A1 (en) *	2007-11-15	2011-09-29	Universite Laval	Methods for the regulation of the prostaglandin f synthase (pgfs) activity of akr1b1 and uses thereof
AR070221A1 (es)	2008-01-23	2010-03-25	Astrazeneca Ab	Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
US20090270490A1 (en) *	2008-04-24	2009-10-29	The Board Of Regents Of The University Of Texas System	Methods involving aldose reductase inhibition
EP2346495B2 (en)	2008-10-07	2023-05-24	Kudos Pharmaceuticals Limited	Pharmaceutical formulation 514
AU2011348074B2 (en)	2010-12-23	2016-04-28	The Board Of Regents Of The University Of Texas System	Methods for treating COPD
US10443185B2 (en)	2016-10-19	2019-10-15	Spectrum Brands, Inc.	Portable steam generator base for iron
US20240033263A1 (en)	2021-03-18	2024-02-01	Banavara MYLARI	Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications
WO2024053761A1 (ko) *	2022-09-07	2024-03-14	애니머스큐어 주식회사	알도오즈 환원효소 억제제를 포함하는 근원 세포 증식 및 분화 촉진용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4492706A (en) *	1983-08-01	1985-01-08	American Home Products Corporation	Method of lowering lipid levels
US4939140A (en) *	1985-11-07	1990-07-03	Pfizer Inc.	Heterocyclic oxophthalazinyl acetic acids
EP0310931A3 (en) *	1987-10-08	1990-10-03	Ethyl Corporation	Poultry feed
FR2665440B1 (fr) *	1990-07-31	1994-02-04	Lipha	Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
US5064830A (en) *	1990-08-02	1991-11-12	Pfizer Inc.	Lowering of blood uric acid levels
JP3049284B2 (ja) *	1990-11-07	2000-06-05	株式会社三和化学研究所	ヒダントイン誘導体並びにそれを有効成分とする糖尿病合併症及び循環器系疾患の予防及び治療剤
US5391551A (en) *	1993-05-10	1995-02-21	Pfizer Inc.	Method of lowering blood lipid levels
US5834466A (en) *	1994-12-22	1998-11-10	The Regents Of The University Of California	Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
CA2208485A1 (en) *	1994-12-22	1996-06-27	Ravichandran Ramasamy	Method for protecting the heart from ischemia
CZ293016B6 (cs) *	1995-06-01	2004-01-14	Sankyo Company Limited	Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem

1997
- 1997-02-20 IL IL12026497A patent/IL120264A0/xx not_active IP Right Cessation
- 1997-02-20 US US08/803,301 patent/US6127367A/en not_active Expired - Fee Related
- 1997-02-21 DE DE69711972T patent/DE69711972T2/de not_active Expired - Fee Related
- 1997-02-21 PT PT97301172T patent/PT792643E/pt unknown
- 1997-02-21 ES ES97301172T patent/ES2172748T3/es not_active Expired - Lifetime
- 1997-02-21 DK DK97301172T patent/DK0792643T3/da active
- 1997-02-21 AT AT97301172T patent/ATE216239T1/de not_active IP Right Cessation
- 1997-02-21 EP EP97301172A patent/EP0792643B1/en not_active Expired - Lifetime
- 1997-02-24 JP JP9039071A patent/JPH09316003A/ja active Pending
- 1997-02-26 CA CA002198564A patent/CA2198564C/en not_active Expired - Fee Related
- 1997-02-27 ZA ZA971717A patent/ZA971717B/xx unknown
- 1997-02-27 CN CN97102574A patent/CN1081460C/zh not_active Expired - Fee Related
- 1997-02-28 KR KR1019970006780A patent/KR970061252A/ko not_active Ceased
- 1997-02-28 AU AU15010/97A patent/AU724327B2/en not_active Ceased

Also Published As

Publication number	Publication date
IL120264A0 (en)	1997-06-10
ES2172748T3 (es)	2002-10-01
KR970061252A (ko)	1997-09-12
JPH09316003A (ja)	1997-12-09
CA2198564C (en)	2000-06-27
ZA971717B (en)	1998-08-27
EP0792643B1 (en)	2002-04-17
CA2198564A1 (en)	1997-08-29
AU1501097A (en)	1997-09-04
CN1168794A (zh)	1997-12-31
DE69711972T2 (de)	2002-08-29
MX9701533A (es)	1998-06-30
EP0792643A1 (en)	1997-09-03
US6127367A (en)	2000-10-03
ATE216239T1 (de)	2002-05-15
DK0792643T3 (da)	2002-07-22
AU724327B2 (en)	2000-09-14
DE69711972D1 (de)	2002-05-23
CN1081460C (zh)	2002-03-27

Publication	Publication Date	Title
ES2172748T3 (es)	2002-10-01	Uso de un inhibidor de aldosa reductasa para la reduccion de daño en tejido no cardiaco.
FI952033A7 (fi)	1995-11-04	Farmakologisesti aktiiviset pyrrolopyrimidiinijohdannaiset
BR9808181B1 (pt)	2009-01-13	uso de um conservante de madeira e bandagem para a pàs-proteÇço de madeira.
DE69027799D1 (de)	1996-08-22	Chemisch amplifizierter Photolack
KR950700906A (ko)	1995-02-20	5-ht1 작동약으로서의 인돌 유도체(indole derivatives as 5-ht1 agonists)
BR9707812A (pt)	1999-07-27	Composto composto farmacêutica e uso do composto
BR9707808A (pt)	1999-07-27	Composto composição farmacêutica e uso do composto
IT1290575B1 (it)	1998-12-10	Dispositivo per la caratterizzazione di fasci laser
FI944727L (fi)	1994-10-07	Indolijohdannaisia 5-HT1:n kaltaisina agonisteina
DE69528843D1 (de)	2002-12-19	Pharmakologisch aktive 2-mercaptobenzimidazolderivate
NO20012584D0 (no)	2001-05-25	Eletriptan hydrobromid monohydrat
DE69710333D1 (de)	2002-03-21	Cyclopentan(en)säure-2-alkenyl-derivate als therapeutika in der behandlung der okulären hypertonie
IT1311753B1 (it)	2002-03-19	Amplificatore a fibra ottica e dispositivo di amplificazione otticaper trasmissione ottica bidirezionale utilizzante l'amplificatore a
ITMI920785A1 (it)	1993-10-01	Microsfere biodegradabili ad uso farmaceutico e cosmetico
AU3347493A (en)	1993-08-03	Pharmaceutically active substituted benzimidazole derivatives
NO20026243L (no)	2003-02-27	7-hydroksyepiandrosteron med neurobeskyttende aktivitet
FI970165L (fi)	1997-03-14	(S)-atenosyyli-L-metioniinin (SAMe) ja sen fysiologisesti hyväksyttävien suolojen käyttö tilapäisen fokaalisen iskemian aiheuttamien reperfuusiovammojen hoitamiseksi
ATE228372T1 (de)	2002-12-15	Hcg und derivate als matrixmetalloprotease- inhibitoren
DK0791355T3 (da)	2002-06-17	Fremgangsmåde til reduktion af vævsbeskadigelse forbundet med iskæmi
IT8848208A0 (it)	1988-07-19	Uso terapeutico del derivato estere isopropilico del monosialogangliosi de in patologie ad interessamento nervoso con componente infiammatoria
IT1291513B1 (it)	1999-01-11	Procedimento e dispositivo per la produzione di una piattina ottica
ITMI921865A0 (it)	1992-07-30	Glicerofosfoderivati farmacologicamente attivi
KR980004704U (ko)	1998-03-30	모니터의 스위블 장치
FR2795143B1 (fr)	2002-05-10	Verin pneumatique telescopique
IT1271356B (it)	1997-05-27	Procedimento per la costruzione di protesi totali oncologiche mascellari, e relative protesi